Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Trends in Diabetes Mellitus and Related Costs Among Hospital Admissions in Switzerland, 2012–2020 Publisher



Obaid HA1, 2, 3 ; Marquesvidal P4
Authors

Source: Diabetology and Metabolic Syndrome Published:2025


Abstract

We assessed 2012-20 trends and costs of hospitalized diabetes mellitus in Switzerland. Hospitalizations due to diabetes mellitus increased by 25%. Hospitalizations with diabetes mellitus as a comorbidity increased by 50%. Costs for hospitalisations rose from 42 to almost 100 million CHF in 2019. © The Author(s) 2025.; Background: In Switzerland, the prevalence of diabetes mellitus (DM) has increased in the general population, but little is known regarding DM-related hospitalizations and their impact on mortality and health costs. Hence, our objectives were to assess (1) the evolution of hospitalizations for DM as first diagnosis and as comorbidity; (2) the association of DM with ICU admission, length of stay (LOS), in-hospital mortality and costs. Methods: Swiss hospital discharge data for period 2012–2020. Type 1 (T1DM), type 2 (T2DM) and other types (OTDM) of DM were considered. Results: Between 2012 and 2020, the number of hospitalizations (% total) increased from 4204 (0.27) to 4980 (0.45) for T2DM, 539 (0.05) to 854 (0.08) for T1DM and 221 (0.02) to 381 (0.03) or OTDM. Hospitalizations with DM as comorbidity increased from 89,752 (8.6) to 128,700 (11.7) for T2DM, 2934 (0.29) to 3536 (0.32) or T1DM and 5774 (0.58) to 9143 (0.83) for OTDM. Compared to non-DM hospitalizations, all types of DM had a higher likelihood of lower limb amputation; hospitalizations for T1DM had a higher likelihood of ICU admission: odds ratio and 95% CI: 3.38 (3.19–3.59), while T2DM had higher LOS: 5.5 ± 1.0 vs. 5.1 ± 1.0 days, and all DM types had a lower odds of in-hospital mortality. Patients with any type of DM as comorbidity had a longer LOS than patients without. Total cost of DM rose from CHF 42 million in 2012 to almost 100 million in 2019 and decreased afterwards. Conclusion: DM represents an increasing health and economic burden in Switzerland. © The Author(s) 2025.
Other Related Docs
18. Cost Effectiveness of Type 2 Diabetes Screening: A Systematic Review, Medical Journal of the Islamic Republic of Iran (2016)